Method of treatment using arylalkylpyridazinones

US6531473B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Rochus Jonas · Darmstadt, DE
• Michael Wolf · Darmstadt, DE
• Norbert Beier · Reinheim, DE

Key dates

• Filing date: Apr 8, 2002
• Grant date: Mar 11, 2003
• Expiry date: Apr 8, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aralkylpyridazinone derivatives of the formula I and their physiologically acceptable saltsin whichR1, R2, R3, R4, R5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflammatory processes and of allergies, asthma and autoimmune disorders.